Cosylab d.d. supports cutting-edge accelerator-based technologies worldwide—from Big Science facilities to advanced medical applications—and brings this same end-to-end expertise to IFIGENEIA’s work on radioisotope production and radiopharmaceuticals.
Cosylab d.d. is a leading provider of the foremost expertise, turnkey software solutions, and electronics for the world’s most advanced systems and devices, such as particle accelerators, fusion reactors, quantum devices, semiconductor manufacturing subsystems and innovative radiation therapy systems.
Our turnkey software solutions enable organisations to make scientific breakthroughs, deliver state-of-the-art cancer treatments, bring clean fusion energy closer, create novel quantum devices and be the first to market with their semiconductor manufacturing solutions. Our engineering is integrated into the most significant Big Science international projects, including CERN and ITER. With our unique end-to-end capabilities, we help organisations of all sizes and scopes accelerate development and shorten time-to-market. We always put in the effort to understand our clients’ unique challenges in accelerator projects and meet them with tailored collaboration and solutions.
Additionally, our experienced engineers and project managers can always supplement your team, ensuring your project meets quality demands and deadlines without compromise. Particle accelerators constantly evolve with new technology, requiring significant effort to maintain reliability and performance. With decades of experience in control systems for all accelerator types, Cosylab helps clients mitigate development risk, shorten delivery time, and reduce the total cost of ownership. From our headquarters in the EU and subsidiaries across Europe, North America, and Asia, we have worked on hundreds of multi-year, multi-person projects worldwide.
Within IFIGENEIA, Cosylab’s primary role is leading T1.2 “Quality assurance, risks, ethics and IPR management” and T3.4 “Control system development project plan”.
